Urol. praxi. 2024;25(2):77-87 | DOI: 10.36290/uro.2024.035

Acute and chronic renal failure

doc. MUDr. Nadežda Petejová, Ph.D., MSc.1, 2, 3, prof. MUDr. Josef Zadražil, CSc.3, 4, doc. MUDr. Arnošt Martínek, CSc.1, 2
1 Interní a kardiologická klinika FN Ostrava
2 Lékařská fakulta Ostravské univerzity
3 III. interní klinika - nefrologická, revmatologická a endokrinologická LF UP, Olomouc
4 III. interní klinika - nefrologická, revmatologická a endokrinologická FN Olomouc

Kidney injury and failure is generally a serious condition in clinical medicine, occurring in almost all fields, including urology. A relatively crucial step in adequate preventive and therapeutic management is early differentiation between acute and chronic renal failure. Each of them requires a different approach but also shares many common features. The present manuscript provides a brief overview of differential diagnostics between the two conditions and basic principles of treatment.

Keywords: acute kidney injury, differential diagnostics, chronic kidney disease.

Accepted: May 31, 2024; Published: June 20, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petejová N, Zadražil J, Martínek A. Acute and chronic renal failure. Urol. praxi. 2024;25(2):77-87. doi: 10.36290/uro.2024.035.
Download citation

References

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney inter., Suppl. 2012;2:1-138.
  2. Xu X, Nie S, Liu Z, et al. Epidemiology and Clinical Correlates of AKI in Chinese Hospitalized Adults. Clin J Am Soc Nephrol. 2015;10(9):1510-1518. Go to original source... Go to PubMed...
  3. Bendall AC, See EJ, Toussaint ND, et al. Community-acquired versus hospital-acquired acute kidney injury at a large Australian metropolitan quaternary referral centre: incidence, associations and outcomes. Intern Med J. 2023;53(8): 1366-1375. Go to original source... Go to PubMed...
  4. White KC, Serpa-Neto A, Hurford R, et al. Queensland Critical Care Research Network (QCCRN). Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study. Intensive Care Med. 2023;49(9):1079-1089. Go to original source... Go to PubMed...
  5. Caddeo G, Williams ST, McIntyre CW, et al. Acute kidney injury in urology patients: incidence, causes and outcomes. Nephrourol Mon. 2013;5(5):955-961. Go to original source... Go to PubMed...
  6. Herrmann SM, Textor SC. Current Concepts in the Treatment of Renovascular Hypertension. Am J Hypertens. 2018;31(2):139-149. Go to original source... Go to PubMed...
  7. Petejová N, Zadražil J, Teplan V, et al. Nefrologie kritických stavů. 1. vydání. Praha: Maxdorf; 2023.
  8. Sanz AB, Sanchez-Niño MD, Ramos AM, et al. Regulated cell death pathways in kidney disease. Nat Rev Nephrol. 2023;19(5):281-299. Go to original source... Go to PubMed...
  9. Li Y, Wang J. Contrast-induced acute kidney injury: a review of definition, pathogenesis, risk factors, prevention and treatment. BMC Nephrol. 2024;25(1):140. Go to original source... Go to PubMed...
  10. Mehran R, Dangas GD, Weisbord SD. Contrast-Associated Acute Kidney Injury. N Engl J Med. 2019;380(22):2146-2155. Go to original source... Go to PubMed...
  11. Ferenbach DA, Bonventre JV. Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol. 2015;11(5):264-276. Go to original source... Go to PubMed...
  12. Juurlink DN, Gosselin S, Kielstein JT, et al. EXTRIP Workgroup. Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Ann Emerg Med. 2015;66(2):165-181. Go to original source... Go to PubMed...
  13. King JD, Kern MH, Jaar BG. Extracorporeal Removal of Poisons and Toxins. Clin J Am Soc Nephrol. 2019;14(9):1408-1415. Go to original source... Go to PubMed...
  14. Calello DP, Liu KD, Wiegand TJ, et al. Extracorporeal Treatments in Poisoning Workgroup. Extracorporeal Treatment for Metformin Poisoning: Systematic Review and Recommendations From the Extracorporeal Treatments in Poisoning Workgroup. Crit Care Med. 2015;43(8):1716-1730. Go to original source... Go to PubMed...
  15. Extracorporeal Treatments in Poisoning Workgroup [online]. Dostupné z: http://www.extrip-workgroup.org.
  16. Dellinger RP, Rhodes A, Evans L, et al. Surviving Sepsis Campaign. Crit Care Med. 2023;51(4):431-444. Go to original source... Go to PubMed...
  17. Joannidis M, Druml W, Forni LG et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med. 2017;43(6):730-749. Go to original source... Go to PubMed...
  18. Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949-1964. Go to original source... Go to PubMed...
  19. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. Go to original source... Go to PubMed...
  20. Viering D, Schlingmann KP, Hureaux M, et al. Genomics England Research Consortium. Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA. J Am Soc Nephrol. 2022;33(2):305-325. Go to original source... Go to PubMed...
  21. Fulchiero R, Seo-Mayer P. Bartter Syndrome and Gitelman Syndrome. Pediatr Clin North Am. 2019;66(1):121-134. Go to original source... Go to PubMed...
  22. Mubarik A, Anastasopoulou C, Riahi S, et al. Liddle Syndrome. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. PMID: 30725596.
  23. Deng Y, Li N, Wu Y, et al. Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019. Front Endocrinol (Lausanne). 2021;12:672350. Go to original source... Go to PubMed...
  24. World Health Organization. Diabetes mellitus. 5. April 2023. Available from: http://www.who.int.
  25. Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Go to original source... Go to PubMed...
  26. Jin Q, Liu T, Qiao Y,et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols. Front Immunol. 2023;14:1185317. Go to original source... Go to PubMed...
  27. Liu D, Lv LL. New Understanding on the Role of Proteinuria in Progression of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:487-500. Go to original source... Go to PubMed...
  28. Patschan D, Patschan S, Ritter O. Chronic Metabolic Acidosis in Chronic Kidney Disease. Kidney Blood Press Res. 2020;45(6):812-822. Go to original source... Go to PubMed...
  29. Klaboch J, Opatrná S, Matoušovic K, et al. Konečné stadium chronického onemocnění ledvin a metabolická acidóza [End stage of chronic kidney disease and metabolic acidosis]. Vnitr Lek. 2012;58(7-8):519-524.
  30. Copur S, Sag AA, Afsar B, et al. Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer. Int Urol Nephrol. 2020;52(12):2311-2320. Go to original source... Go to PubMed...
  31. Batchelor EK, Kapitsinou P, Pergola PE, et al. Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment. J Am Soc Nephrol. 2020;31(3):456-468. Go to original source... Go to PubMed...
  32. Ku E, Del Vecchio L, Eckardt KU, et al. for Conference Participants. Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023;104(4):655-680. Go to original source... Go to PubMed...
  33. Wang B, Li ZL, Zhang YL, et al. Hypoxia and chronic kidney disease. EBioMedicine. 2022;77:103942. Go to original source... Go to PubMed...
  34. Sampani E, Theodorakopoulou M, Iatridi F, et al. Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy. Expert Opin Pharmacother. 2023;24(16):1775-1789. Go to original source... Go to PubMed...
  35. Borrelli S, Matarazzo I, Lembo E, et al. Chronic Hyperkaliemia in Chronic Kidney Disease: An Old Concern with New Answers. Int J Mol Sci. 2022;23(12):6378. Go to original source... Go to PubMed...
  36. Ramirez-Sandoval JC, Madero M. Treatment of Hyperuricemia in Chronic Kidney Disease. Contrib Nephrol. 2018;192: 135-146. Go to original source... Go to PubMed...
  37. Lim YJ, Sidor NA, Tonial NC, et al. Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. Toxins (Basel). 2021;13(2):142. Go to original source... Go to PubMed...
  38. Ketteler M, Block GA, Evenepoel P, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. Kidney Int. 2017;92(1):26-36. Go to original source... Go to PubMed...
  39. Evenepoel P, Stenvinkel P, Shanahan C, et al. Inflammation and gut dysbiosis as drivers of CKD-MBD. Nat Rev Nephrol. 2023;19(10):646-657. Go to original source... Go to PubMed...
  40. Yamada S, Nakano T. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD. J Atheroscler Thromb. 2023;30(8):835-850. Go to original source... Go to PubMed...
  41. Pazianas M, Miller PD. Osteoporosis and Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): Back to Basics. Am J Kidney Dis. 2021;78(4):582-589. Go to original source... Go to PubMed...
  42. Rosner MH, Reis T, Husain-Syed F, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. Clin J Am Soc Nephrol. 2021;16(12):1918-1928. Go to original source... Go to PubMed...
  43. Sternlicht H, Bakris GL. The Kidney in Hypertension. Med Clin North Am. 2017;101(1):207-217. Go to original source... Go to PubMed...
  44. Ameer OZ. Hypertension in chronic kidney disease: What lies behind the scene. Front Pharmacol. 2022; 13:949260. Go to original source... Go to PubMed...
  45. Park CH, Kim HW, Joo YS, et al; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators. Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression. Kidney Int. 2024;105(4):835-843. Go to original source... Go to PubMed...
  46. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. Go to original source... Go to PubMed...
  47. Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684-701. Go to original source... Go to PubMed...
  48. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99(3S):S1-S87. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.